The central question about Collective is not simply what its medications cost. It is who takes responsibility at each stage: reviewing an online assessment, deciding whether to prescribe, dispensing the preparation, managing delivery and responding when treatment needs attention. Collective markets those steps as a connected experience, with messaging, check-ins and refrigerated shipping. Its legal documents describe a more divided structure: CollectiveOS supplies the platform, while independent medical practices and pharmacies provide the clinical and dispensing services.
This review follows that care pathway using public documentation consulted October 19, 2026: two substantially duplicated commercial pages, the terms and the privacy policy. The advertised prices are concrete—$59 monthly for compounded semaglutide or $69 monthly for compounded tirzepatide, plus a $199 annual membership—but several operational details remain unspecified. The useful distinction is between what Collective promises to arrange, what its independent partners must deliver and what a prospective patient still needs confirmed before paying or transferring care.
At a glance
- Care model
- CollectiveOS says it is a membership-based intermediary, not a medical provider, and does not employ or supervise the clinicians providing care.Sources: [4]
- Published prices
- Compounded semaglutide is advertised at $59/month and compounded tirzepatide at $69/month, at any dose, with medication billed separately from a $199 annual membership.Sources: [5]
- Trial and renewal
- The advertised 21-day membership trial does not include free medication. Terms make trial eligibility conditional and provide for automatic annual membership renewal.
- Geographic availability
- The site advertises service in 44 states, excluding Alabama, California, Louisiana, Massachusetts, Mississippi and Washington; terms exclude users outside the United States.
- Delivery and follow-up
- Collective advertises two-day express cold shipping after approval, unlimited doctor messaging, quarterly check-ins and live group Q&As with registered dietitians.Sources: [5]
Start by identifying the platform and the medical practice
The site identifies its legal entity as Health for Everyone Inc., doing business as CollectiveOS, and publishes a Houston mailing address. The terms describe an online membership platform facilitating telehealth consultations and prescription wellness products, including GLP-1s, through independent licensed healthcare providers and pharmacies. That supports describing Collective as a GLP-1 access service, but not as the medical practice itself. Its contractual role is coordination and technology rather than direct clinical care.
The distinction is explicit: CollectiveOS says it does not provide medical advice or care, own or operate the medical practices, or employ or supervise their clinicians. Control over treatment rests with the independent practices and providers. The privacy policy names MDIntegrations and its network of independent medical groups as an example of consultation partners; it does not establish that every patient will see that particular organization.
Before enrollment, ask for the name of the practice responsible for your consultation and how to reach it independently of billing support. Our guide to the clinician–platform distinction explains why that identification matters. Here, the split is especially consequential because the commercial page describes one coordinated membership experience while the terms assign clinical responsibility elsewhere. A single login should not be mistaken for a single organization responsible for every service.
What happens between the health assessment and a prescription
Collective says enrollment begins with a brief online health assessment covering medical history, goals and previous GLP-1 experience. Its commercial page says no in-person visit or laboratory work is needed to begin, and that a U.S.-licensed doctor usually reviews the information within a day or two. That wording describes the starting process and a typical review interval; it does not establish that laboratory testing could never be requested later or that every application receives a decision on that schedule.
The terms establish three separate requirements for obtaining a prescription product: a consultation through the platform, a provider's determination that the product is appropriate and an issued prescription. Completing the questionnaire or paying therefore does not guarantee medication. Collective also advertises a full refund if the doctor determines treatment is unsuitable and says patients are not charged for medication they do not receive. The documentation does not fully reconcile that promise with its broader nonrefund provisions.
The pages do not publish complete clinical approval criteria, including BMI thresholds, comorbidities or contraindications. Their age language also conflicts: terms contemplate parental permission for users under 18, while the privacy policy says the platform is not intended for them and prohibits their submission of personal information. Adults should still confirm geographic eligibility: the advertised six-state exclusion is specific, and access is limited to available U.S. states rather than users abroad.
What the membership pays for—and what remains separate
Collective advertises compounded semaglutide at $59 per month and compounded tirzepatide at $69 per month, with the same medication price at any dose. Those are not complete membership-inclusive prices: medication is billed separately from the $199 annual membership. The consulted documentation does not specify the preparations' administration route, presentation, additional ingredients or quantity supplied per shipment. It also does not define the advertised month as a four-week supply, so neither presentation nor supply length should be inferred from the price.
The membership is advertised as covering personalized doctor-prescribed protocols, unlimited doctor messaging, ongoing check-ins and adjustments, nutrition and lifestyle support, and express cold shipping. The headline says no multi-month orders are required. However, the terms reserve a possible technology transaction fee for each electronic prescription transmission, regardless of pharmacy selected, without publishing an amount. That qualification matters beside the commercial assurance that nothing is added on top of membership and medication.
Collective says it does not bill insurance. It also says medication and membership may qualify for HSA/FSA reimbursement, with the plan administrator deciding what is reimbursable; that is not a reimbursement guarantee. Before authorizing payment, obtain an itemized explanation of the first charge, subsequent medication billing and any transmission fee. The documentation also leaves unclear whether auxiliary medications, supplies or later laboratory testing could create separate expenses.
| Item | Published arrangement | Point to confirm |
|---|---|---|
| Compounded semaglutide | $59/month; advertised same price at any dose | Route, presentation and shipment quantity |
| Compounded tirzepatide | $69/month; advertised same price at any dose | Route, presentation and shipment quantity |
| Membership | $199 annually, separate from medication | First annual charge date and renewal date |
| 21-day trial | Membership offer; medication remains payable | Eligibility and features included at signup |
| Prescription transmission | Terms permit a technology transaction fee | Amount and when it applies |
The pharmacy handoff needs more detail than an ingredient name
Collective states that every prescription is written by a U.S.-licensed doctor, filled by a state-licensed U.S. pharmacy and associated with batches tested by a third party for purity and potency. These are provider claims, not independent findings from this review. The consulted pages do not identify the dispensing pharmacies by name or provide certificates of analysis or independent license documentation. They also do not establish which entity compounds a preparation; dispensing and compounding are different responsibilities.
The terms allow patients to fill a prescription at a pharmacy of their choice, as prompted during use of the service. That is useful contractual flexibility, but the pages do not explain whether the advertised medication prices or included cold shipping apply outside the arranged pharmacy channel. Ask for the dispensing pharmacy's identity, exact formulation, presentation, labeling and contact information before fulfillment. The pharmacy-handoff checklist can help organize those questions without assuming every pharmacy offers the same product.
FDA explains that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence or prove anything about this particular service. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Collective's testing statements do not substitute for that patient-specific discussion or establish FDA approval of its preparations.
Two-day shipping is one stage, not the whole delivery timeline
After approval, Collective advertises medication cold-shipped by two-day express service to the patient's door. Its membership description includes express cold shipping. That shipping claim sits after clinical review, which the company separately says usually takes one or two days. Neither statement supplies a complete application-to-arrival deadline: the pages do not specify order preparation time, the carrier, dispatch schedules or what happens when a shipment is delayed.
For someone transferring care, the practical question is when a usable, correctly identified package will arrive—not merely when a doctor reviews the assessment. Ask who provides tracking, who handles delivery exceptions and which party authorizes replacement for loss or a temperature problem. The documentation does not establish those procedures. Our explanation of approval, dispatch and arrival separates the clocks that can otherwise become a misleading expectation of delivery two days after signup.
Although the reviewed pages do not specify the administration route, FDA's refrigeration advice matters if the prescribed product is injectable: do not use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contact the provider or dispensing pharmacy. The existence of a cold-shipping promise does not settle whether a particular package remained adequately refrigerated. Before ordering, obtain the pharmacy's instructions and the correct contact route for a questionable delivery.
Follow-up is advertised, but response standards are not
Collective's follow-up offering is more specific than a generic promise of support. It advertises unlimited doctor messaging, quarterly check-ins, ongoing adjustments, live group Q&As with registered dietitians and practical nutrition and lifestyle resources. Those are distinct services: a group nutrition session is not the same as an individual prescribing consultation. The pages do not specify messaging hours, response targets, the format of quarterly reviews or whether Spanish-language consultations and resources are available.
For people already taking a GLP-1, Collective offers transition support and says the current dose may be maintained if the doctor approves. Changing between treatments likewise requires approval. Neither promise guarantees continuation of an existing prescription. Ask what records the receiving practice needs, when it reviews them and who remains responsible during the transfer. The pages describe support but do not provide a detailed transfer schedule or a complete process for sharing records with a previous clinician.
The terms expressly exclude emergencies and urgent situations, and recommend maintaining a local primary care relationship because these services do not replace it. NIDDK describes medication follow-up as attention to response and tolerability, not just continued payment. That makes the missing response standards meaningful: patients should know which problems belong in routine messaging and where to seek timely care outside the platform. “Unlimited” describes access volume, not a promise of immediate clinical attention.
Ending payments is different from arranging continuing care
The commercial page offers 21 days without a membership charge, during which medication remains payable. It says cancellation before the trial ends avoids the annual membership fee. The terms are narrower: new users may qualify for a limited trial covering certain platform features, as described at signup. Save the actual enrollment terms and the trial end date rather than assuming the general advertisement defines every account's offer or includes a free medication trial.
Membership renews automatically each year unless canceled online before the current period ends. Collective advertises account-based cancellation without telephone calls, and the terms say access continues through the paid period. Cancellation does not mean a refund: membership fees and partial periods are generally nonrefundable except where law requires or purchase terms expressly provide otherwise. A separate provision says services and products cannot be returned and are nonrefundable unless CollectiveOS determines otherwise.
The advertised refund for clinical rejection should therefore be confirmed in writing, including which charges it covers and how to request it. Likewise, the commercial statement that a transferring patient's price is locked should not be treated as an unlimited price guarantee: terms permit membership price changes with advance communication, effective for the next membership period. Before leaving, distinguish stopping renewal from transferring prescriptions and records; the changing-program questions address that practical separation.
Know where records, support requests and unresolved questions go
Collective's privacy policy separates ordinary platform information from protected health information associated with consultations and prescription fulfillment. It says the latter is governed by applicable health-information laws and the provider's Notice of Privacy Practices, which CollectiveOS must follow when using or disclosing that information. Prospective patients should request the medical practice's notice as well as reading the platform policy. The two documents address different parts of a service involving several organizations.
The policy permits sharing personal information with pharmacy and telehealth partners, payment processors, shipping and logistics partners, hosting and storage services, analytics providers and other support vendors. It states that contractual restrictions require confidentiality and use for the disclosed purposes. The site publishes questions@collective.org and (832) 280-7898 in its messaging-help language. Those are documented contact paths, but their publication does not establish clinical availability, response times or an urgent-care channel.
The most useful final check is a responsibility list: the medical practice for prescribing and follow-up, the dispensing pharmacy for product questions, and the platform for membership and account issues. Ask each party how records or requests move between them. The documentation establishes the broad division but leaves important operating details open. It supports an assessment of the advertised service model—not verification of individual clinicians, pharmacy licenses, batch quality or patient outcomes.
Questions & answers
Does Collective itself provide the medical care?
No, according to its terms. CollectiveOS facilitates access, while independent medical practices and providers control clinical care. The privacy policy mentions MDIntegrations and its network as an example. Ask which practice will handle your consultation and follow-up; the brand name alone does not identify your treating organization.
Are the $59 and $69 monthly prices the full cost?
No. They are advertised medication prices for compounded semaglutide and compounded tirzepatide, respectively. A separate $199 annual membership applies after the qualifying trial. Terms also permit an unspecified prescription-transmission technology fee. Confirm the itemized checkout amount, billing dates and whether that fee applies to your prescription.
Can I use a pharmacy I choose?
The terms permit filling an issued prescription at a pharmacy of your choice, as prompted through the service. They do not establish that Collective's advertised medication prices or shipping benefits follow the prescription elsewhere. Confirm pharmacy participation, availability, fulfillment charges and who will answer product questions before directing the prescription.
Will medication arrive two days after I sign up?
That is not what the pages establish. Collective separately describes doctor review usually within one or two days and two-day express cold shipping after approval. It does not publish a complete application-to-receipt timeline or preparation schedule. Ask when dispatch is expected and how delivery problems are handled.
Can I transfer while keeping my current treatment?
Collective advertises supported transfers and possible continuation of the current dose with doctor approval. It is not guaranteed. Ask what previous records are required, when the receiving doctor will decide and how follow-up responsibility changes. Switching between the advertised treatments also requires medical approval.
Does canceling my membership produce a refund?
Generally not under the published terms. Online cancellation stops renewal, with account access continuing through the paid period; membership and partial-period fees are generally nonrefundable. The commercial page separately promises a full refund for clinical rejection. Confirm that exception's scope rather than assuming all cancellations qualify.
Our assessment
Collective documents a recognizable care pathway: online assessment, independent prescribing, pharmacy fulfillment, refrigerated shipping and continuing messaging and check-ins. Its published medication prices and annual membership are clear enough to discuss directly, and its terms acknowledge pharmacy choice. The weaker points are at the handoffs: unnamed pharmacies, unspecified formulations and supply quantities, no complete delivery timeline, no messaging response standards and an unpriced potential transaction fee. Trial, refund and price-lock marketing also require reading alongside narrower contractual language. For prospective patients, the strongest next step is to obtain the treating practice's identity, pharmacy and product details, an itemized payment schedule and written instructions for delivery or follow-up problems. The documents establish advertised access, not independently verified quality or treatment results.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.